The WM Trial clinical research study is no longer enrolling. Results of this phase 1b study will help determine at what dosage the investigational study drug, mavorixafor, is well-tolerated by people with WM in combination with ibrutinib.
Enter your email address to receive updates about the WM Trial and other X4 Pharmaceuticals news.